.svg)
Work has begun on the analysis of clinical data regarding the adherence and persistence of patients undergoing intravitreal injections for wet macular degeneration. The data, commissioned by two commercial customers will be of immense interest to the doctors involved in the patients' care too.
Very importantly, no patient nor doctor will be at all identifiable - the data analytics will be aggregated and remain unidentifiable for all Macuject analyses now and in the future; data privacy in clinical care is paramount and cannot be compromised.
Our customers are particularly interested in the ways in which patients' adherence to recommended treatment may affect their outcomes. Through thiese analyses we willbe able to assess how various measures may influence outcomes, as we aim to use Macuject to bring about positive change and better visual outcomes.